Viking Therapeutics (VKTX) Deemed 'Extremely Attractive' and Undervalued by Canaccord, Cited as Leader in Obesity Clinical Development

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord raised the firm’s price target on Viking Therapeutics to $107 from $106 with a Buy rating on the shares. Canaccord considers Viking Therapeutics’ shares to be significantly undervalued, especially when factoring in the more advanced stage of the company’s obesity pipeline. Canaccord currently regards Viking Therapeutics as an extremely attractive asset within the obesity therapeutic area and recognizes it as the leading biotech company in obesity clinical development.

In Q3 2025, Viking Therapeutics highlighted significant progress in its obesity pipeline, particularly for the dual GLP-1/GIP receptor agonist, VK2735, but also reported a substantial increase in net loss driven by clinical trial expenses. The company reported an increase in its net loss for Q3, which totaled $90.8 million or $0.81 per share, compared to a net loss of $24.9 million or $0.22 per share in Q3 2024. This increase was primarily driven by a sharp rise in R&D expenses, which soared to $90 million for Q3 2025, up from $22.8 million in the same quarter of 2024.

Viking Therapeutics also announced positive top-line results from a Phase 2 clinical trial of the oral tablet formulation of VK2735, which showed statistically significant reductions in body weight compared with placebo. The company’s pivotal Phase 3 VANQUISH Obesity program for the subcutaneous formulation is advancing well. Furthermore, Viking is advancing a novel maintenance dosing study for VK2735, which explores various dosing regimens to maintain weight loss and potentially enhance long-term treatment adherence.

Viking Therapeutics Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company that develops novel therapies for metabolic and endocrine disorders.

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.